Empower Your
Medical Affairs
Team with AI
Gain deeper field knowledge, answer complex questions faster, and stay ahead of scientific trends.
How A79 helps
A79 empowers Medical Affairs teams with AI-driven tools ultimately driving better engagement and strategic decision-making. We offer a range of customized solutions to fit your team’s needs.
Field Insights
Capture and analyze health care professional (HCP) opinions of medicinal products, treatments and unmet medical needs.
Automated early detection of emerging safety and efficacy signals.
Competitive intelligence and automated surveillance.
2 new Adverse events found :
3 HCPs reported Gastrointestinal issues due to GLPs. View raw data
Ocular Toxicities: 2 Dry Eye syndrome were found. View raw data
What are the results if CancerX drug is combined with radiation therapy.
There is no conclusive studies which combine results of radiation therapy with CancerX. However there are a few the ongoing studies (Link 1, Link 2), which show proof of concept for patients with liver metastases.
Complex Questions
Rapid, accurate and nuanced answers to complex medical questions.
Fully documented with citations and references.
Drill down to underlying sources cited and referenced.
Scientific Surveillance
Automated monitoring of targeted literature and scientific sources.
Dynamic summarizations.
Trend identification and implication categorization; commercial, clinical, regulatory.
Found 2 new papers from Mark Lewis (KOL, Oncology).
Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC Read | Generate summary
Disunited State of Cancer Care in America Read | Generate summary
The features
Medical Affairs
teams love
Conversational flow
Ask questions in natural language and receive instant, actionable answers. No coding or complex queries required.
We integrate with internal as well as external data sources to give you the most accurate information.
Request a demo
How many treatments are we evaluating?
What’s the main insight from this data?
Here are the main insights from the data provided:
1. Treatment Preferences in 3rd Line aCRC:
CANCERX + bevacizumab (TFD/PTI + Bev) is widely adopted as the standard of care in 3rd line aCRC treatment
This combination is preferred over monotherapy options
Fruquintinib is emerging as a potential 4th line option or for patients with poor performance status
2. Clinical Experience with CANCERX + Bev:
Generally well-tolerated with manageable side effects
Some practices use growth factor support (WBCS) to manage cytopenlas
Alternate dosing schedules (e.g., biweekly) are sometimes used to manage toxicity
3. Biomarker Testing:
cDNA testing is gaining interest but its clinical utility is still being evaluated
Some KOLs are cautious about over-reliance on cIDNA for treatment decisions
GPA (genomic profile analysis) testing practices vary among oncologists.
Your data includes 5 treatments. What would you like to explore next?
Advanced Filters
Drill down into your data with powerful filters that isolate specific cohorts, time frames, and variables.
Charts
Transform your data into compelling visuals that reveal hidden trends and patterns. Easily customize and share your insights.
Dashboards with re-usable insights
Create interactive dashboards with customizable widgets to monitor key metrics and share insights across your organization.
Configure email alerts when there are significant changes to the answers in a dashboard.
Request a demo
Add to dashboard
Product Information: LYTGOBI (Futibatinib)
Based on the information provided in the table, here's a summary of the feedback and key insights about the product LYTGOBI (Futibatinib):
Efficacy
1. Good response rates and long duration of response:
Patients have shown responses lasting >2 years
Good efficacy reported, making it a go-to option for FGFR2 fusion or gene rearrangement
Exciting response rate and longer duration of response
PFS is longer than anticipated
2. Potential for use in specific patient populations:
• May be used immediately after first-line treatment in patients unable to tolerate Cisplatin
Safety and Adverse Events
1. Nail toxicities:
Case studies
See A79 in Action
Discover how A79 is driving measurable productivity improvements for our partners
The platform's AI-powered insights allow us to tailor our medical communications and deliver the right information to the right audience at the right time. This has significantly improved our engagement and strengthened our relationships with key opinion leaders.
Head of Medical Affairs
Leading Pharmaceutical Company
A79 has been a true partner in our AI journey, working hand-in-hand with us to build custom solutions that are not only powerful but also incredibly user-friendly. The platform has been enthusiastically embraced by our entire team.
Head of AI development
Leading Oncology Company
A79 has completely transformed my workflow. I can now access critical scientific information, prepare for HCP interactions, and generate insightful reports in a fraction of the time it used to take.
Senior MSL
Top 20 Pharma
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
Copyright A79® 2024